In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

Clostridioides difficile is a bacterial pathogen responsible for significant morbidity and mortality across the globe. Current therapies based on broad-spectrum antibiotics have some clinical success, but approximately 30% of patients have relapses, presumably due to the continued perturbation to th...

Full description

Bibliographic Details
Main Authors: Kurt Selle, Joshua R. Fletcher, Hannah Tuson, Daniel S. Schmitt, Lana McMillan, Gowrinarayani S. Vridhambal, Alissa J. Rivera, Stephanie A. Montgomery, Louis-Charles Fortier, Rodolphe Barrangou, Casey M. Theriot, David G. Ousterout
Format: Article
Language:English
Published: American Society for Microbiology 2020-03-01
Series:mBio
Subjects:
clostridioides difficile
crispr-cas
cas3
phage
lysogeny
crispr
Online Access:https://doi.org/10.1128/mBio.00019-20

Internet

https://doi.org/10.1128/mBio.00019-20

Similar Items